AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39224752 — intervention group
Group type: COMPARATOR
Intervention: Center-based cardiac rehabilitation
Number of subjects: 900
Study 39224799 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted telenursing
Number of subjects: 0
Study 39224811 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with paclitaxel (50 mg/m2) and carboplatin (AUC=2) followed by concurrent CRT with the same regimen, radiation dose of 40 Gy over 16 fractions (2.5 Gray/fraction).
Number of subjects: 54
Study 39224901 — intervention group
Group type: EXPERIMENTAL
Intervention: CMAB015 (150 mg)
Number of subjects: 130
Study 39224901 — intervention group
Group type: COMPARATOR
Intervention: Secukinumab (Cosentyx)
Number of subjects: 130
Study 39224986 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led family empowerment program (experimental group)
Number of subjects: 58
Study 39224986 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 58
Study 39225259 — intervention group
Group type: EXPERIMENTAL
Intervention: Plozasiran 25 mg
Number of subjects: 75
Study 39225259 — intervention group
Group type: EXPERIMENTAL
Intervention: Plozasiran 50 mg
Number of subjects: 75
Study 39225259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 39225259 — intervention group
Group type: EXPERIMENTAL
Intervention: Plozasiran (both doses)
Number of subjects: 75
Study 39225258 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban monotherapy
Number of subjects: 1040
Study 39225258 — intervention group
Group type: COMPARATOR
Intervention: Dual antithrombotic therapy (edoxaban plus a single antiplatelet agent)
Number of subjects: 1040
Study 39225267 — intervention group
Group type: EXPERIMENTAL
Intervention: Asundexian 50 mg once daily
Number of subjects: 14810
Study 39225267 — intervention group
Group type: COMPARATOR
Intervention: Apixaban (standard dose)
Number of subjects: 14810
Study 39225327 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarcopenia
Number of subjects: 500
Study 39225384 — intervention group
Group type: EXPERIMENTAL
Intervention: LifeFirst SWASTH program (pamphlet explaining tobacco's harmful effects, brief cessation advice, referral for free telephone counseling for 6 months)
Number of subjects: 1687
Study 39225384 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet explaining tobacco's harmful effects (no brief advice or counseling)
Number of subjects: 1687
Study 39225437 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidental AF during programmed electrical stimulation (PES)
Number of subjects: 231
Study 39225437 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with incidental AF during PES
Number of subjects: 231
Study 39225437 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradyarrhythmia risk
Number of subjects: 231
Study 39225437 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular arrhythmias risk
Number of subjects: 231
Study 39225437 — intervention group
Group type: EXPERIMENTAL
Intervention: Major cardiovascular events (MACE) risk
Number of subjects: 231
Study 39225478 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine (NVX-CoV2373)
Number of subjects: 1299
Study 39225478 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine (mRNA-1273)
Number of subjects: 1299
Study 39225478 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 vaccine (AZD1222)
Number of subjects: 1299
Study 39225478 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 vaccine (Ad26.COV2.S)
Number of subjects: 1299
Study 39225598 — intervention group
Group type: EXPERIMENTAL
Intervention: Encorafenib plus binimetinib
Number of subjects: 0
Study 39225603 — intervention group
Group type: EXPERIMENTAL
Intervention: Restaging MRI
Number of subjects: 277
Study 39225612 — intervention group
Group type: EXPERIMENTAL
Intervention: Histotripsy treatment
Number of subjects: 44
Study 39225647 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (ages 65 to < 75 years, n = 923 patients)
Number of subjects: 1636
Study 39225647 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (ages ≥ 75 years, n = 713 patients)
Number of subjects: 1636
Study 39225647 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1636
Study 39225647 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1
Number of subjects: 1636
Study 39225647 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2
Number of subjects: 1636
Study 39225670 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (666 mg dose 3 times daily)
Number of subjects: 30
Study 39225670 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 30
Study 39225842 — intervention group
Group type: EXPERIMENTAL
Intervention: Online delivered running/walking group program
Number of subjects: 72
Study 39225842 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 72
Study 39225890 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir/Lamivudine (DTG/3TC)
Number of subjects: 493
Study 39225890 — intervention group
Group type: COMPARATOR
Intervention: Current antiretroviral regimen (CAR)
Number of subjects: 493
Study 39226027 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudge+ (EHR documentation template plus facilitation)
Number of subjects: 46397
Study 39226027 — intervention group
Group type: COMPARATOR
Intervention: Nudge (EHR documentation template only)
Number of subjects: 46397
Study 39226070 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide, 2.4 mg
Number of subjects: 3377
Study 39226070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3377
Study 39226076 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 521
Study 39226076 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 521
Study 39226076 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy (BT)
Number of subjects: 521
Study 39226076 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 521
Study 39226081 — intervention group
Group type: EXPERIMENTAL
Intervention: Talquetamab 0.4 mg/kg weekly (QW)
Number of subjects: 0
Study 39226081 — intervention group
Group type: EXPERIMENTAL
Intervention: Talquetamab 0.8 mg/kg every other week (Q2W)
Number of subjects: 0
Study 39226081 — intervention group
Group type: EXPERIMENTAL
Intervention: Talquetamab Q2W
Number of subjects: 0
Study 39226081 — intervention group
Group type: EXPERIMENTAL
Intervention: Talquetamab QW
Number of subjects: 0
Study 39226187 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated micro portable gas chromatography device for breath analysis
Number of subjects: 60
Study 39226187 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 60
Study 39226237 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular intervention (EVT)
Number of subjects: 0
Study 39226247 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-ADL (Cognitive Stimulation in Activities of Daily Living)
Number of subjects: 34
Study 39226247 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 34
Study 39226247 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-ADL
Number of subjects: 34
Study 39226288 — intervention group
Group type: EXPERIMENTAL
Intervention: β-alanine supplementation (5g per dosage, total 155g over 7 days)
Number of subjects: 11
Study 39226288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 39226292 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Tamoxifen (LDT) at 10 mg every other day
Number of subjects: 200
Study 39226292 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention (LI, step counter use)
Number of subjects: 200
Study 39226292 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Tamoxifen (LDT) + Intermittent caloric restriction (ICR)
Number of subjects: 200
Study 39226292 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention (LI) + Intermittent caloric restriction (ICR)
Number of subjects: 200
Study 39226457 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboinflammation measured as H3Cit-DNA complexes on day 1 after STEMI
Number of subjects: 361
Study 39226457 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboinflammation at day 1 after STEMI
Number of subjects: 361
Study 39226457 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic analysis
Number of subjects: 361
Study 39226457 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression analysis
Number of subjects: 361
Study 39226514 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimodality therapy (radiation with radiosensitizing chemotherapy)
Number of subjects: 34
Study 39226615 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 26
Study 39226615 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise
Number of subjects: 26
Study 39226615 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise
Number of subjects: 26
Study 39226615 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 26
Study 39226693 — intervention group
Group type: EXPERIMENTAL
Intervention: BLTR-3 (bilamellar tarsal rotation with a 3 mm incision height)
Number of subjects: 4914
Study 39226693 — intervention group
Group type: EXPERIMENTAL
Intervention: BLTR-5 (bilamellar tarsal rotation with a 5 mm incision height)
Number of subjects: 4914
Study 39226693 — intervention group
Group type: EXPERIMENTAL
Intervention: PLTR (posterior lamellar tarsal rotation)
Number of subjects: 4914
Study 39226693 — intervention group
Group type: COMPARATOR
Intervention: BLTR-3
Number of subjects: 4914
Study 39226693 — intervention group
Group type: COMPARATOR
Intervention: BLTR-5
Number of subjects: 4914
Study 39226704 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous (IO) administration of 2-g TXA prehospital bolus; 11 participants
Number of subjects: 966
Study 39226704 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) administration of 2-g TXA prehospital bolus; 334 participants
Number of subjects: 966
Study 39226704 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous (IO) administration of 1-g TXA prehospital bolus followed by 1-g TXA infusion in-hospital over 8 hours; 13 participants
Number of subjects: 966
Study 39226704 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) administration of 1-g TXA prehospital bolus followed by 1-g TXA infusion in-hospital over 8 hours; 299 participants
Number of subjects: 966
Study 39226719 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE)
Number of subjects: 162
Study 39226719 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (LCD)
Number of subjects: 162
Study 39226719 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of TRE and LCD (TRE + LCD)
Number of subjects: 162
Study 39227284 — intervention group
Group type: EXPERIMENTAL
Intervention: efgartigimod PH20 SC 1000 mg
Number of subjects: 0
Study 39227284 — intervention group
Group type: COMPARATOR
Intervention: efgartigimod IV 10 mg/kg
Number of subjects: 0
Study 39227284 — intervention group
Group type: EXPERIMENTAL
Intervention: efgartigimod PH20 SC
Number of subjects: 0
Study 39227399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26-MVA
Number of subjects: 0
Study 39227399 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSV
Number of subjects: 0
Study 39227399 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSV-booster
Number of subjects: 0
Study 39227450 — intervention group
Group type: EXPERIMENTAL
Intervention: D-VMP
Number of subjects: 215
Study 39227450 — intervention group
Group type: COMPARATOR
Intervention: VMP
Number of subjects: 215
Study 39227453 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk CEP72 TT genotype (rs924607)
Number of subjects: 499
Study 39227453 — intervention group
Group type: COMPARATOR
Intervention: CC or CT genotypes
Number of subjects: 499
Study 39227452 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab-bendamustine-prednisone
Number of subjects: 15
Study 39227508 — intervention group
Group type: EXPERIMENTAL
Intervention: ESK981 160 mg once daily for 5 days per week for 4 weeks per cycle
Number of subjects: 13
Study 39227508 — intervention group
Group type: EXPERIMENTAL
Intervention: ESK981
Number of subjects: 13
Study 39227583 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab (200 mg IV) every three weeks for two cycles
Number of subjects: 10
Study 39227626 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D2
Number of subjects: 228
Study 39227626 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention
Number of subjects: 228
Study 39227626 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D adequate (> 30 ng/mL)
Number of subjects: 228
Study 39227662 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronavigation-assisted stereotactic drilling drainage (MIS group)
Number of subjects: 67
Study 39227662 — intervention group
Group type: COMPARATOR
Intervention: Craniotomy haematoma removal surgery (CHRS group)
Number of subjects: 67
Study 39227769 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS patients
Number of subjects: 260
Study 39227769 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 260
Study 39227818 — intervention group
Group type: EXPERIMENTAL
Intervention: FOS-fructans (2.1 g/day)
Number of subjects: 59
Study 39227818 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten (5.7 g/day)
Number of subjects: 59
Study 39227818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 39227842 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month intensive lifestyle intervention
Number of subjects: 60
Study 39227842 — intervention group
Group type: COMPARATOR
Intervention: Control group (sarcopenia subjects before intervention)
Number of subjects: 60
Study 39227873 — intervention group
Group type: COMPARATOR
Intervention: Normotensive pregnant women (n=30)
Number of subjects: 60
Study 39227873 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women with late-onset preeclampsia (n=30)
Number of subjects: 60
Study 39227893 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG analysis of relative spectral power in delta bands at frontal and central points during rest
Number of subjects: 0
Study 39227893 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG analysis of relative spectral power in alpha bands at frontal and central points during rest
Number of subjects: 0
Study 39227893 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG analysis of relative spectral power in delta bands at central points during rest
Number of subjects: 0
Study 39227897 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% Silver Diamine Fluoride (SDF) applied at one-month intervals
Number of subjects: 84
Study 39227897 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% Silver Diamine Fluoride (SDF) applied at four-month intervals
Number of subjects: 84
Study 39227897 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% Silver Diamine Fluoride (SDF) applied at six-month intervals
Number of subjects: 84
Study 39227910 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous branch pulmonary artery interventions
Number of subjects: 0
Study 39227910 — intervention group
Group type: COMPARATOR
Intervention: Conservative management for 6 months
Number of subjects: 0
Study 39227911 — intervention group
Group type: EXPERIMENTAL
Intervention: Bootle Blast (8-week upper limb home-based intervention)
Number of subjects: 15
Study 39227921 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (LCD)
Number of subjects: 169
Study 39227921 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 h time-restricted eating (TRE)
Number of subjects: 169
Study 39227921 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of LCD and TRE
Number of subjects: 169
Study 39227921 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 169
Study 39227929 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-obese with 0 CKM comorbidities (Group 1)
Number of subjects: 2105
Study 39227929 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese with 3 CKM comorbidities (Group 6)
Number of subjects: 2105
Study 39228007 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-initiated buprenorphine program
Number of subjects: 0
Study 39228063 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal phenotype assessment of AKS cases (including novel case)
Number of subjects: 20
Study 39228063 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrops assessment in AKS cases
Number of subjects: 20
Study 39228131 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (200/540 mg daily for 3 days)
Number of subjects: 1526
Study 39228131 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (40/960 mg daily for 3 days)
Number of subjects: 1526
Study 39228660 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered palliative (CP) stent dilation
Number of subjects: 0
Study 39228783 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam rolling at different speeds
Number of subjects: 18
Study 39228845 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmodified KF94 mask
Number of subjects: 100
Study 39228845 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmodified KN95 mask
Number of subjects: 100
Study 39228845 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified surgical mask
Number of subjects: 100
Study 39228845 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified KN95 mask
Number of subjects: 100
Study 39228858 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant porcine factor VIII (rpFVIII; susoctocog alfa)
Number of subjects: 50
Study 39228893 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated patients (198 cases)
Number of subjects: 437
Study 39228893 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated patients (117 cases)
Number of subjects: 437
Study 39228893 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall DKD cohort
Number of subjects: 437
Study 39228893 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic nephropathy (DN) group
Number of subjects: 437
Study 39228895 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysphagia Symptom Questionnaire (DSQ)
Number of subjects: 239
Study 39229259 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac and IIV4 followed by PPV23
Number of subjects: 636
Study 39229259 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac and PPV23 followed by IIV4
Number of subjects: 636
Study 39229259 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac followed by IIV4 and PPV23
Number of subjects: 636
Study 39229259 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of IIV4 and PPV23
Number of subjects: 636
Study 39229259 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccine combinations
Number of subjects: 636
Study 39229263 — intervention group
Group type: EXPERIMENTAL
Intervention: Chidamide + CHOP
Number of subjects: 66
Study 39229263 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 66
Study 39229263 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplanted group
Number of subjects: 66
Study 39229468 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalpiciclib (150 mg) plus letrozole/anastrozole
Number of subjects: 104
Study 39229468 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalpiciclib (150 mg) plus fulvestrant
Number of subjects: 104
Study 39229468 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalpiciclib (175 mg) plus letrozole/anastrozole
Number of subjects: 104
Study 39229468 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalpiciclib (175 mg) plus fulvestrant
Number of subjects: 104
Study 39229468 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalpiciclib (lower doses) plus letrozole/anastrozole
Number of subjects: 104
Study 39229468 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalpiciclib (lower doses) plus fulvestrant
Number of subjects: 104
Study 39229471 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants (primarily LMWH and direct oral anticoagulants)
Number of subjects: 1804
Study 39229471 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelets (primarily aspirin)
Number of subjects: 1804
Study 39229471 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants
Number of subjects: 1804
Study 39229471 — intervention group
Group type: EXPERIMENTAL
Intervention: Any grade ⩾3 adverse events
Number of subjects: 1804
Study 39229700 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency renal denervation (RDN)
Number of subjects: 217
Study 39229700 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 217
Study 39229707 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 3986
Study 39229707 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 3986
Study 39229707 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAF episodes (1 to 5 episodes)
Number of subjects: 3986
Study 39229707 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAF episodes (≥6 episodes)
Number of subjects: 3986
Study 39229707 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous SCAF with no episode ≥6 minutes
Number of subjects: 3986
Study 39229707 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one SCAF episode in 6 months before enrollment
Number of subjects: 3986
Study 39229786 — intervention group
Group type: EXPERIMENTAL
Intervention: Ripretinib
Number of subjects: 0
Study 39229786 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 0
Study 39229805 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)
Number of subjects: 400
Study 39229807 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic stroke patients' experiences
Number of subjects: 9
Study 39229807 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 9
Study 39229807 — intervention group
Group type: EXPERIMENTAL
Intervention: Current care strategies
Number of subjects: 9
Study 39230120 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibostolimab
Number of subjects: 0
Study 39230120 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibostolimab combined with pembrolizumab
Number of subjects: 0